Hellerup, Denmark, August 5, 2014. Azanta A/S, a Danish specialty pharmaceutical company, today announced that they have entered an exclusive option agreement with Hamlet Pharma AB to acquire the rights to develop and commercialize the novel oncology compound HAMLET (human alpha-lactalbumin made lethal to tumor cells).
HAMLET is a human molecule that is proven to kill more than 40 different types of cancer cells, including some that are difficult to treat with available drugs by its natural non-toxic mechanism. The molecule has been characterized in the laboratory, and its mechanism of action has been documented by a group of scientists led by Professor Catharina Svanborg from Lund University in Sweden.
Dr. Claus Møller, Chief Executive Officer of Azanta, commented: "Hamlet has shown very promising results in pre-clinical and clinical testing, and we believe there is a strong rationale for advancing the project and evaluating Hamlet in colorectal polyposis and colon cancer".
HAMLET is a complex between human alpha-lactalbumin and oleic acid that induces apoptosis in tumor cells, but not in healthy cells. HAMLET is a novel chemotherapeutic agent with potent tumoricidal properties. Alpha-lactalbumin is the primary protein component of human breastmilk.
--- ooo ---
About Azanta A/S
Azanta A/S is a privately owned specialty pharma company primarily operating within oncology, women´s health and addiction medicine. The vision of Azanta A/S is to become an international market leader within specialty pharma products and innovative pharmaceutical products. Azanta A/S currently markets or makes available a string of specialty pharma products, including Nimoral, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy. In addition, Azanta A/S has a portfolio of low risk development projects for commercialization within the near future.
For further information, please visit www.azanta.com.
Tel: + 45 - 70 25 95 45
Fax: + 45 - 70 25 95 46